论文信息 - HER-2/neu immunotherapies: Take two – get more: optimization strategies for HER-2/neu-based immunotherapies inhibiting carcinogenesis - 字舞流文

HER-2/neu immunotherapies: Take two – get more: optimization strategies for HER-2/neu-based immunotherapies inhibiting carcinogenesis

B. Seliger | R. Kiessling

[1] Piero Musiani,et al. Concordant morphologic and gene expression data show that a vaccine halts HER-2/neu preneoplastic lesions. , 2004, The Journal of clinical investigation.

[2] Piero Musiani,et al. DNA Vaccination Against Rat Her-2/Neu p185 More Effectively Inhibits Carcinogenesis Than Transplantable Carcinomas in Transgenic BALB/c Mice1 2 , 2000, The Journal of Immunology.

[3] S. Ménard,et al. p185neu protein is required for tumor and anchorage‐independent growth, not for cell proliferation of transgenic mammary carcinoma , 2000, International journal of cancer.

[4] R. Cardiff,et al. The mammary pathology of genetically engineered mice: the consensus report and recommendations from the Annapolis meeting‡ , 2000, Oncogene.

[5] B. Seliger,et al. Small interfering RNA (siRNA) inhibits the expression of the Her2/neu gene, upregulates HLA class I and induces apoptosis of Her2/neu positive tumor cell lines , 2004, International journal of cancer.

[6] A Choudhury,et al. Cellular immunity to the Her-2/neu protooncogene. , 2002, Advances in cancer research.